IndraLab
Statements
sparser
"In metastatic colorectal cancer, mutations in KRAS , BRAF and PIK3CA are associated with resistance to treatment with monoclonal antibodies cetuximab and panitumumab, which target the extracellular domain of EGFR (Di Nicolantonio et al, xref ; Lievre et al, xref ; Sartore-Bianchi et al, xref )."